News stories about Emergent Biosolutions (NYSE:EBS) have trended somewhat positive recently, according to Accern. The research firm scores the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Emergent Biosolutions earned a news sentiment score of 0.02 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 44.570874971279 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- 2 Biotech Stocks with Month-Long Upward Estimate Revisions (zacks.com)
- Emergent Biosolutions (EBS) Lowered to “Hold” at Zacks Investment Research (americanbankingnews.com)
- Should You Get Rid of Peregrine Pharmaceuticals (PPHM) Now? (zacks.com)
- Sanofi/Alnylam Say FDA Lifts Clinical Hold on Fitusiran (finance.yahoo.com)
- Brokerages Anticipate Emergent Biosolutions, Inc. (EBS) Will Post Quarterly Sales of $182.16 Million (americanbankingnews.com)
Emergent Biosolutions (NYSE:EBS) opened at $46.94 on Thursday. The company has a current ratio of 7.37, a quick ratio of 6.46 and a debt-to-equity ratio of 0.38. Emergent Biosolutions has a twelve month low of $27.94 and a twelve month high of $47.37. The firm has a market cap of $1,910.81, a P/E ratio of 24.42, a PEG ratio of 1.33 and a beta of 1.24.
EBS has been the subject of several research reports. BidaskClub raised shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a report on Friday, August 25th. Zacks Investment Research raised shares of Emergent Biosolutions from a “hold” rating to a “buy” rating and set a $45.00 price objective for the company in a report on Wednesday, October 25th. Finally, Wells Fargo & Company reissued an “outperform” rating and set a $43.00 price objective (up from $41.00) on shares of Emergent Biosolutions in a report on Saturday, September 30th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Emergent Biosolutions has an average rating of “Buy” and an average price target of $46.00.
In related news, Director Ronald Richard sold 1,266 shares of the business’s stock in a transaction that occurred on Wednesday, September 27th. The shares were sold at an average price of $40.00, for a total transaction of $50,640.00. Following the completion of the sale, the director now directly owns 24,676 shares in the company, valued at $987,040. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Adam Havey sold 7,885 shares of the business’s stock in a transaction that occurred on Wednesday, September 27th. The shares were sold at an average price of $39.50, for a total transaction of $311,457.50. Following the sale, the executive vice president now owns 33,931 shares of the company’s stock, valued at $1,340,274.50. The disclosure for this sale can be found here. Insiders have sold 280,989 shares of company stock valued at $11,700,343 over the last three months. 16.50% of the stock is owned by corporate insiders.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
What are top analysts saying about Emergent Biosolutions? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Emergent Biosolutions and related companies.